PL2902026T3 - Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie - Google Patents

Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie

Info

Publication number
PL2902026T3
PL2902026T3 PL15151582T PL15151582T PL2902026T3 PL 2902026 T3 PL2902026 T3 PL 2902026T3 PL 15151582 T PL15151582 T PL 15151582T PL 15151582 T PL15151582 T PL 15151582T PL 2902026 T3 PL2902026 T3 PL 2902026T3
Authority
PL
Poland
Prior art keywords
treatment
mediated disease
inflammation mediated
metabolic inflammation
thiazolidinedione analogues
Prior art date
Application number
PL15151582T
Other languages
English (en)
Polish (pl)
Inventor
Gerard R. Colca
Rolf F. KLETZIEN
Original Assignee
Metabolic Solutions Development Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Development Company Llc filed Critical Metabolic Solutions Development Company Llc
Publication of PL2902026T3 publication Critical patent/PL2902026T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL15151582T 2006-03-16 2007-03-14 Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie PL2902026T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78289406P 2006-03-16 2006-03-16
EP15151582.2A EP2902026B1 (en) 2006-03-16 2007-03-14 Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
EP12166539A EP2486926A1 (en) 2006-03-16 2007-03-14 Thiazolidinedione Analogues
EP07752982A EP2001468B1 (en) 2006-03-16 2007-03-14 Thiazolidinedione analogues

Publications (1)

Publication Number Publication Date
PL2902026T3 true PL2902026T3 (pl) 2018-03-30

Family

ID=38328199

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15151582T PL2902026T3 (pl) 2006-03-16 2007-03-14 Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie
PL07752982T PL2001468T3 (pl) 2006-03-16 2007-03-14 Analogi tiazolidynodionu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07752982T PL2001468T3 (pl) 2006-03-16 2007-03-14 Analogi tiazolidynodionu

Country Status (15)

Country Link
US (4) US20090143442A1 (enExample)
EP (3) EP2001468B1 (enExample)
JP (2) JP5269758B2 (enExample)
KR (1) KR101475955B1 (enExample)
CN (1) CN101454005B (enExample)
AU (1) AU2007227581B2 (enExample)
CA (1) CA2646207C (enExample)
ES (2) ES2654908T3 (enExample)
HU (1) HUE035314T2 (enExample)
MX (2) MX2008011871A (enExample)
NZ (1) NZ571871A (enExample)
PL (2) PL2902026T3 (enExample)
RU (1) RU2445957C2 (enExample)
UA (1) UA96441C2 (enExample)
WO (1) WO2007109024A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001470A2 (en) * 2006-03-16 2008-12-17 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues
PL2001469T3 (pl) 2006-03-16 2012-10-31 Metabolic Solutions Dev Co Llc Analogi tiazolidynodionu
EP2001468B1 (en) 2006-03-16 2012-10-31 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
BRPI0817096B8 (pt) 2007-09-14 2021-05-25 Cirius Therapeutics Inc análogo de tiazolidinodiona e composição farmacêutica que o compreende
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
PE20151924A1 (es) 2008-08-12 2016-01-13 Zinfandel Pharmaceuticals Inc Metodo de identificacion de factores de riesgo de la enfermedad
KR20120092712A (ko) * 2009-12-15 2012-08-21 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 진성 당뇨병 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
MX2012006730A (es) * 2009-12-15 2012-07-30 Metabolic Solutions Dev Co Llc Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
KR20120107493A (ko) * 2009-12-15 2012-10-02 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
GB2477743A (en) * 2010-02-10 2011-08-17 Argenta Therapeutics Ltd Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2011133441A2 (en) * 2010-04-19 2011-10-27 Metabolic Solutions Development Company Novel synthesis for thiazolidinedione compounds
US8937182B2 (en) 2010-04-19 2015-01-20 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
JP5927190B2 (ja) 2010-08-10 2016-06-01 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー チアゾリジンジオン化合物のための新規合成
CA2807815C (en) 2010-08-10 2018-10-02 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
MA34828B1 (fr) 2011-01-10 2014-01-02 Zinfandel Pharmaceuticals Inc Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer
WO2012114204A2 (en) * 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
WO2014046474A2 (ko) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
KR101501375B1 (ko) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
AU2013359903A1 (en) * 2012-12-11 2015-07-02 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3024816B1 (en) 2013-07-22 2020-06-03 Metabolic Solutions Development Company LLC Ppar-sparing compounds for the treatment of metabolic diseases
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
KR102418167B1 (ko) 2014-04-02 2022-07-08 미노릭스 테라퓨틱스 에스.엘. 중추 신경계 장애의 치료에서의 2,4-티아졸리딘디온 유도체
HRP20210576T1 (hr) 2016-12-01 2021-05-28 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion, namijenjen liječenju nealkoholne masne bolesti jetre
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1985004170A1 (fr) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
WO1986002073A1 (fr) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
WO1992018501A1 (en) * 1991-04-11 1992-10-29 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ES2296288T3 (es) * 1993-09-15 2008-04-16 Daiichi Sankyo Company, Limited Uso de tiazolidinodionas para evitar o retardar el comienzo de la diabetes mellitus no insulina dependiente (niddm).
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TW474809B (en) 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
EE200300519A (et) 2001-04-26 2004-02-16 L�civa, a.s. Meetod pioglitasooni kui suhkurtõvevastase aine saamiseks
JPWO2005054213A1 (ja) * 2003-12-02 2007-12-06 塩野義製薬株式会社 ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
EP2001468B1 (en) 2006-03-16 2012-10-31 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
PL2001469T3 (pl) 2006-03-16 2012-10-31 Metabolic Solutions Dev Co Llc Analogi tiazolidynodionu
EP2001470A2 (en) * 2006-03-16 2008-12-17 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues
BRPI0817096B8 (pt) 2007-09-14 2021-05-25 Cirius Therapeutics Inc análogo de tiazolidinodiona e composição farmacêutica que o compreende

Also Published As

Publication number Publication date
US9155729B2 (en) 2015-10-13
US20120015982A1 (en) 2012-01-19
UA96441C2 (ru) 2011-11-10
CN101454005B (zh) 2013-01-02
KR20090037381A (ko) 2009-04-15
AU2007227581A1 (en) 2007-09-27
AU2007227581B2 (en) 2012-11-08
RU2008140943A (ru) 2010-04-27
RU2445957C2 (ru) 2012-03-27
CA2646207A1 (en) 2007-09-27
ES2654908T3 (es) 2018-02-15
ES2654908T8 (es) 2018-04-11
JP2013100371A (ja) 2013-05-23
MX2008011871A (es) 2009-02-10
ES2397944T3 (es) 2013-03-12
PL2001468T3 (pl) 2013-03-29
KR101475955B1 (ko) 2014-12-23
NZ571871A (en) 2011-07-29
CN101454005A (zh) 2009-06-10
EP2001468A2 (en) 2008-12-17
WO2007109024A3 (en) 2007-11-15
US20130203820A1 (en) 2013-08-08
CA2646207C (en) 2016-01-19
EP2486926A1 (en) 2012-08-15
HUE035314T2 (en) 2018-05-02
US20090143442A1 (en) 2009-06-04
JP2009530283A (ja) 2009-08-27
WO2007109024A2 (en) 2007-09-27
EP2001468B1 (en) 2012-10-31
EP2902026B1 (en) 2017-10-04
JP5269758B2 (ja) 2013-08-21
US20150190385A1 (en) 2015-07-09
EP2902026A1 (en) 2015-08-05
US8389556B2 (en) 2013-03-05
MX356584B (es) 2018-06-05

Similar Documents

Publication Publication Date Title
PL2902026T3 (pl) Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
ZA200808963B (en) Compounds for the treatment of metabolic disorders
IL193747A0 (en) New therapeutic combinations for the treatment of depression
SI2056842T1 (sl) Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
IL194189A0 (en) Combination treatment of metabolic disorders
IL192852A0 (en) Compounds for the treatment of metabolic disorders
ZA200806808B (en) Treatment of stressed patients
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
GB0909297D0 (en) Composition for the treatment of skin conditions
PT2076268E (pt) Roscovitina para o tratamento de certas doenças císticas
IL195392A0 (en) Compounds for the treatment of metabolic disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
IL192982A0 (en) Compounds for the treatment of metabolic disorders
GB0623740D0 (en) Treatment of disease
GB0618309D0 (en) Compositions and methods for the treatment of disease
GB0602857D0 (en) The treatment of sialorrhoea
AU2007905975A0 (en) Treatment of metabolic disease 2
AU2007905974A0 (en) Treatment of metabolic disease 1
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
GB0602858D0 (en) The treatment of sialorrhoea